Informa (INF) H2 2020 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2020 earnings summary
23 Oct, 2026Executive summary
FY20 performance broadly matched guidance; COVID-19 sharply reduced physical event activity, while subscription businesses remained resilient. 2021 positioned as a transition year before recovery and growth through 2024.
Priorities included balance-sheet stability, disciplined costs and cash, continued investment in subscription businesses, and rebuilding physical events alongside digital services.
Financial highlights
FY20 revenue was £1.661bn; adjusted operating profit was nearly £270m, with adjusted operating margin of 16%.
A £593m non-cash goodwill impairment was recognized at H1; no additional impairment was required at year-end, and the year ended with an operating loss.
Cost actions delivered over £600m of run-rate savings by year-end: £400m+ direct and £200m+ indirect; in-year indirect savings were about £140m.
Free cash outflow was £150m for FY20, better than H1 guidance of £230m–£250m; initiatives generated about £100m of free cash flow before one-off COVID-related outflows.
Net debt declined YoY, supported by the equity raise; Q1 2021 was cash-flow positive, with the FY21 baseline designed for cash-flow neutrality or better.
Outlook and guidance
FY21 revenue baseline reaffirmed at £1.7bn, supported by subscription growth, mainland China events, digital services and outdoor events; international event revenue is excluded from guidance.
FY21 is a transition year; any revenue upside depends chiefly on the pace of North American physical-event reopening. Further guidance was expected at the H1 update in July.
Intelligence underlying revenue growth guidance raised to 4%+; Taylor & Francis expected to return to growth in FY21 after essentially flat FY20 revenue.
Physical events are expected to return progressively during 2021, supporting stronger participation and performance in 2022; growth acceleration is anticipated across the business through 2024.
At £1.7bn revenue, FY21 free cash flow is expected to be modestly positive, rather than material, following cost-base resizing.
Latest events from Informa
- Global pharma events pair supply-chain reach with data-led growth opportunities.INF
Investor presentation - 9M revenue grew 6.5%; double-digit adjusted EPS growth guidance was reaffirmed.INF
Q3 2026 TU - Strong 2019 cash generation met COVID-19 disruption with ~£450m of events rescheduled.INF
H2 2019 - Revenue, cash and earnings grew as exhibitions and U.S. scale reshaped the portfolio.INF
H2 2016 - Underlying growth reached 3.7% as UBM integration advanced and synergies set up 2019.INF
H2 2018 - Strong cash generation and rising dividends funded a measured growth and portfolio reset.INF
H2 2014 - Record 26.4% operating margin, strong cash generation and lower debt marked FY2011.INF
H2 2011 - Revenue rose 30.7%, underlying growth accelerated, and 2018 growth target topped 3.5%.INF
H2 2017 - 10.1% five-month growth, a £0.5bn buyback and a Q4 2024 TechTarget target.INF
AGM 2024 & Trading update